113 related articles for article (PubMed ID: 38883375)
1. FBXL18 is required for ovarian cancer cell proliferation and migration through activating AKT signaling.
Zhuang Y; Xue J; Qiu X; Zhu Y; Lv J; Xia F
Am J Transl Res; 2024; 16(5):1977-1990. PubMed ID: 38883375
[TBL] [Abstract][Full Text] [Related]
2. The F-box protein FBXL18 promotes glioma progression by promoting K63-linked ubiquitination of Akt.
Zhang J; Yang Z; Ou J; Xia X; Zhi F; Cui J
FEBS Lett; 2017 Jan; 591(1):145-154. PubMed ID: 27926990
[TBL] [Abstract][Full Text] [Related]
3. Elevated FBXL18 promotes RPS15A ubiquitination and SMAD3 activation to drive HCC.
Yu HQ; Li F; Xiong H; Fang L; Zhang J; Bie P; Xie CM
Hepatol Commun; 2023 Jul; 7(7):. PubMed ID: 37378633
[TBL] [Abstract][Full Text] [Related]
4. OCT4 induces EMT and promotes ovarian cancer progression by regulating the PI3K/AKT/mTOR pathway.
Xie W; Yu J; Yin Y; Zhang X; Zheng X; Wang X
Front Oncol; 2022; 12():876257. PubMed ID: 36033461
[TBL] [Abstract][Full Text] [Related]
5. CNOT7 modulates biological functions of ovarian cancer cells via AKT signaling pathway.
Yu J; Hu X; Chen X; Zhou Q; Jiang Q; Shi Z; Zhu H
Life Sci; 2021 Mar; 268():118996. PubMed ID: 33412213
[TBL] [Abstract][Full Text] [Related]
6. Ubiquitin ligase TRIM22 inhibits ovarian cancer malignancy via TCF4 degradation.
Tao T; Zhang Y; Guan C; Wang S; Liu X; Wang M
Mol Cancer Res; 2024 Jun; ():. PubMed ID: 38842601
[TBL] [Abstract][Full Text] [Related]
7. MiR-198 inhibits proliferation, invasion and migration of ovarian cancer cells by regulating the PI3K/Akt signaling pathway.
Xiao H; Zheng Y; Chen J; Shen H
Acta Biochim Pol; 2021 Jun; 68(4):673-677. PubMed ID: 34181826
[TBL] [Abstract][Full Text] [Related]
8. Tongguanteng injection reverses paclitaxel resistance via upregulation of TAB1 expression in ovarian cancer in vitro and in vivo.
Kong QW; Yang J; Li D; Ding YW; Hu YJ; Xue XC; Shi MZ; Jiang B; Zhou YY; Zhang M; Hu JD; Guo C; Chen JJ; Han YL
J Ethnopharmacol; 2023 Jan; 300():115728. PubMed ID: 36126783
[TBL] [Abstract][Full Text] [Related]
9. Effect of siRNA-silencing of SALL2 gene on growth, migration and invasion of human ovarian carcinoma A2780 cells.
Miao F; Zhang X; Cao Y; Wang Y; Zhang X
BMC Cancer; 2017 Dec; 17(1):838. PubMed ID: 29228922
[TBL] [Abstract][Full Text] [Related]
10. DMBT1 suppresses cell proliferation, migration and invasion in ovarian cancer and enhances sensitivity to cisplatin through galectin-3/PI3k/Akt pathway.
Ma N; Zhao Y
Cell Biochem Funct; 2020 Aug; 38(6):801-809. PubMed ID: 32424818
[TBL] [Abstract][Full Text] [Related]
11. Fbxl18 targets LRRK2 for proteasomal degradation and attenuates cell toxicity.
Ding X; Barodia SK; Ma L; Goldberg MS
Neurobiol Dis; 2017 Feb; 98():122-136. PubMed ID: 27890708
[TBL] [Abstract][Full Text] [Related]
12. LncRNA WDFY3-AS2 promotes cisplatin resistance and the cancer stem cell in ovarian cancer by regulating hsa-miR-139-5p/SDC4 axis.
Wu Y; Wang T; Xia L; Zhang M
Cancer Cell Int; 2021 May; 21(1):284. PubMed ID: 34051810
[TBL] [Abstract][Full Text] [Related]
13. PRR11 Overexpression Facilitates Ovarian Carcinoma Cell Proliferation, Migration, and Invasion Through Activation of the PI3K/AKT/β-Catenin Pathway.
Zhu J; Hu H; Wang J; Yang Y; Yi P
Cell Physiol Biochem; 2018; 49(2):696-705. PubMed ID: 30165366
[TBL] [Abstract][Full Text] [Related]
14. IMP3 accelerates the progression of prostate cancer through inhibiting PTEN expression in a SMURF1-dependent way.
Zhang X; Wang D; Liu B; Jin X; Wang X; Pan J; Tu W; Shao Y
J Exp Clin Cancer Res; 2020 Sep; 39(1):190. PubMed ID: 32938489
[TBL] [Abstract][Full Text] [Related]
15. TPX2 gene silencing inhibits cell proliferation and promotes apoptosis through negative regulation of AKT signaling pathway in ovarian cancer.
Tian Y; Liu LL; Guo DM; Wang Y; Zha WH; Li Y; Wu FJ
J Cell Biochem; 2018 Sep; 119(9):7540-7555. PubMed ID: 29904936
[TBL] [Abstract][Full Text] [Related]
16. ANGPTL4 regulates ovarian cancer progression by activating the ERK1/2 pathway.
Xu J; Wu F; Zhu Y; Wu T; Cao T; Gao W; Liu M; Qian W; Feng G; Xi X; Hou S
Cancer Cell Int; 2024 Feb; 24(1):54. PubMed ID: 38311733
[TBL] [Abstract][Full Text] [Related]
17. HRD1 functions as a tumor suppressor in ovarian cancer by facilitating ubiquitination-dependent SLC7A11 degradation.
Wang Y; Wang S; Zhang W
Cell Cycle; 2023 May; 22(9):1116-1126. PubMed ID: 36809917
[TBL] [Abstract][Full Text] [Related]
18. NUF2 promotes tumorigenesis by interacting with HNRNPA2B1 via PI3K/AKT/mTOR pathway in ovarian cancer.
Ren M; Zhao H; Gao Y; Chen Q; Zhao X; Yue W
J Ovarian Res; 2023 Jan; 16(1):17. PubMed ID: 36670423
[TBL] [Abstract][Full Text] [Related]
19. BCKDK Promotes Ovarian Cancer Proliferation and Migration by Activating the MEK/ERK Signaling Pathway.
Li H; Yu D; Li L; Xiao J; Zhu Y; Liu Y; Mou L; Tian Y; Chen L; Zhu F; Duan Q; Xue P
J Oncol; 2022; 2022():3691635. PubMed ID: 35498541
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of Long Noncoding RNA H19 Downregulates miR-140-5p and Activates PI3K/AKT Signaling Pathway to Promote Invasion, Migration and Epithelial-Mesenchymal Transition of Ovarian Cancer Cells.
Xu H; Ding Y; Yang X
Biomed Res Int; 2021; 2021():6619730. PubMed ID: 34250088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
